These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34260044)

  • 21. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
    Burden AD; Bissonnette R; Anatchkova M; Budhiarso I; Skalicky AM; Liberato ACS; Hu N; Thoma C; Gloede T; Kohlmann T; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1383-1390. PubMed ID: 38334243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
    Langley RG; Feldman SR; Nyirady J; van de Kerkhof P; Papavassilis C
    J Dermatolog Treat; 2015 Feb; 26(1):23-31. PubMed ID: 24354461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis.
    Wilson HD; Mutebi A; Revicki DA; Mease PJ; Genovese MC; Erondu N; Nirula A; Yuan FJ; Viswanathan HN
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1750-6. PubMed ID: 26206134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychometric Evaluation of a New Patient-Reported Outcome (PRO) Symptom Diary for Varicose Veins: VVSymQ(®) Instrument.
    Wright DD; Paty J; Turner-Bowker DM; Bradbury A
    Patient; 2016 Aug; 9(4):335-48. PubMed ID: 27016239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity.
    Bushnell DM; Martin ML; McCarrier K; Gordon K; Chiou CF; Huang X; Ortmeier B; Kricorian G
    J Dermatolog Treat; 2013 Oct; 24(5):356-60. PubMed ID: 23092173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychometric Validation and Meaningful Change Thresholds of the New Nasal Polyposis Symptom Diary.
    Shih VH; Slagle AF; Ivanescu C; Flore G; Meyers O; Kreindler J; Martin UJ; Werkström V
    Ann Otol Rhinol Laryngol; 2023 Dec; 132(12):1638-1648. PubMed ID: 37271980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
    Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.
    He Z; Lu C; Basra MK; Ou A; Yan Y; Li L
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):109-15. PubMed ID: 22145712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity.
    Silverberg JI; Agner T; Baranowski K; Plohberger U; Thoning H; Arbuckle R; Grant L; Skingley G; Bissonnette R
    Arch Dermatol Res; 2024 Mar; 316(4):110. PubMed ID: 38507100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychometric evaluation of the near activity visual questionnaire presbyopia (NAVQ-P) and additional patient-reported outcome items.
    Sims J; Sloesen B; Bentley S; Naujoks C; Arbuckle R; Chiva-Razavi S; Pascoe B; Stochl J; Findley A; O'Brien P; Wolffsohn JS
    J Patient Rep Outcomes; 2024 Apr; 8(1):41. PubMed ID: 38592339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.